Faculty of Veterinary and Agricultural Sciences, The University of Melbourne, Parkville, Victoria, 3010, Australia.
Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria, 3052, Australia.
Parasit Vectors. 2019 Jun 17;12(1):306. doi: 10.1186/s13071-019-3537-1.
Here, the scientific and patent literature on the activities of purified natural compounds has been reviewed, with the aim of assessing their suitability as anthelmintic drug discovery starting points. Only compounds described as active against parasitic nematodes of animals or against the model nematode Caenorhabditis elegans have been analysed. Scientific articles published since 2010 and patents granted from 2000, both inclusive, have been included in this analysis. The results show a scarcity of novel chemical structures, a limited follow-up of compounds disclosed before 2010 and a bias towards the screening of plant products, almost to the exclusion of other sources, when microbial extracts have, historically, provided most starting points for anti-infective drugs. All plant products published in this period were previously known, alerting to the high re-discovery rates of a limited number of chemical classes from this source. The most promising compounds described in the literature reviewed here, namely the linear nemadectin-derivatives, are novel and of bacterial origin. Patented but otherwise unpublished spiroketal structures also appear as interesting scaffolds for future development. The patent literature confirmed that it is possible to patent derivatives of previously known products, making them valid starting points for translational research.
本文回顾了有关天然化合物活性的科学文献和专利文献,旨在评估其作为抗寄生虫药物发现起点的适用性。仅分析了那些被描述为对动物寄生线虫或模式线虫秀丽隐杆线虫有活性的化合物。本分析包括 2010 年以后发表的科学文章和 2000 年以后授予的专利。结果表明,新颖的化学结构稀缺,对 2010 年以前披露的化合物的后续研究有限,而且偏向于筛选植物产品,几乎排除了其他来源,而历史上微生物提取物为抗感染药物提供了大多数起点。本期间公布的所有植物产品均为已知产品,这表明从该来源大量重复发现少数几种化学类别的高再发现率。在本文所回顾的文献中描述的最有前途的化合物,即线性米尔贝肟衍生物,是新颖的,且源自细菌。专利文献证实,对以前已知产品的衍生物进行专利保护,使其成为转化研究的有效起点是可行的。